Objective-To characterize the course of neuropsychiatric symptoms (NPS) in adults with mild cognitive impairment (MCI), and to examine baseline individual-level predictors and associated cognitive and functional outcomes.
Studies that have evaluated NPS at one time point may be insufficient to characterize a patient's NPS burden because they give a static view of an essentially dynamic set of symptoms. This is further complicated when using datasets that have entry criteria restricting the use of psychotropics or the type and severity of NPS at screening, essentially injecting a bias in the sample selection when it comes to the examination of NPS. The heterogeneous patterns of NPS that patients experience may provide a means of predicting which patients with MCI are most at risk for developing AD. To our knowledge, no studies have examined the heterogeneity in NPS trajectories over time in MCI and their relationship to cognitive and functional outcomes. characteristics were associated with particular courses of NPS. Finally, we examined whether different NPS courses predicted cognitive and functional outcomes over time.
Methods

Study sample
Data used in the preparation of this article were obtained from the Alzheimer's Disease Neuroimaging Initiative (ADNI) database (adni.loni.usc.edu). The ADNI was launched in 2003 by the National Institute on Aging (NIA), the National Institute of Biomedical Imaging and Bioengineering (NIBIB), the Food and Drug Administration (FDA), private pharmaceutical companies and non-profit organizations, as a $60 million, 5-year publicprivate partnership. The primary goal of ADNI has been to test whether serial magnetic resonance imaging (MRI), positron emission tomography (PET), other biological markers, and clinical and neuropsychological assessment can be combined to measure the progression of mild cognitive impairment (MCI) and early Alzheimer's disease (AD). Determination of sensitive and specific markers of very early AD progression is intended to aid researchers and clinicians to develop new treatments and monitor their effectiveness, as well as lessen the time and cost of clinical trials.
The Principal Investigator of this initiative is Michael W. Weiner, MD, VA Medical Center and University of California -San Francisco. ADNI is the result of efforts of many coinvestigators from a broad range of academic institutions and private corporations, and subjects have been recruited from over 50 sites across the U.S. and Canada. The initial goal of ADNI was to recruit 800 subjects but ADNI has been followed by ADNI-GO and ADNI-2. To date these three protocols have recruited over 1500 adults, ages 55 to 90, to participate in the research, consisting of cognitively normal older individuals, people with early or late MCI, and people with early AD. The follow up duration of each group is specified in the protocols for ADNI-1, ADNI-2 and ADNI-GO. Subjects originally recruited for ADNI-1 and ADNI-GO had the option to be followed in ADNI-2. For up-to-date information, see www.adni-info.org.
Participants
The present study used data obtained July 2014 from ADNI. Our sample included 560 older adults who began ADNI-1 with a diagnosis of MCI, or who were newly enrolled in ADNI-GO or ADNI-2 with a diagnosis of late MCI (lMCI), which had the same diagnostic criteria as a diagnosis of MCI in ADNI-1. The MCI group included participants with amnestic single-and multiple-domain MCI. Each participant was enrolled with a study partner who could provide functional evaluation.
The diagnosis of MCI or lMCI was made by a psychiatrist or neurologist at each study site and reviewed by a Central Review Committee. Diagnoses were based on a subjective memory complaint and performance on neurocognitive testing, including the Logical Memory II subscale of the Wechsler Memory Scale-Revised (score ≤ 8, cut-off adjusted for education level), the Mini-Mental State Exam (MMSE; score 24 -30) , and the Clinical Dementia Rating (CDR; global score = 0.5). These subjects did not meet the NINCDS-ADRDA criteria for AD. 19 ADNI entry criteria exclude use of antidepressants with significant anticholinergic side effects (other antidepressants were allowed in stable doses), neuroleptics, chronic anxiolytics or sedative hypnotics for at least 4 weeks prior to screening. Furthermore, active major depression or bipolar disorder within the past 12 months as well as psychotic features, agitation, or behavioral problems within the last three months prior to screening that the investigators believed could lead to difficulty complying with the protocol were exclusionary. This limits the severity of NPS at study entry.
Assessment of NPS
NPS were evaluated using the Neuropsychiatric Inventory Questionnaire (NPI-Q). 20 The NPI-Q asked the study partner whether a patient had exhibited NPS in the past 30 days in each of twelve symptom domains. If the informant answered "no" to a screening question, that domain was scored as 0; if the informant answered "yes", he or she was asked to rate the severity of the symptom from 1 (mild) to 3 (severe). Total scores ranged from 0 to 36, higher scores indicating worse symptoms. 20 Individual items were also analyzed as dichotomous variables based on the absence or presence of the particular symptom. The NPI-Q was administered at baseline and every six months thereafter for two years, either in person or over the phone.
Baseline demographic and health information
Basic demographic information, including age, sex, and years of formal education were obtained during screening. Additional data included a blood draw, which was analyzed for APOE4 (having ≥ 1 allele defined carrier status), and a structural MRI.
Outcome measures
All outcomes were assessed at baseline and every six months for two years thereafter.
Diagnostic outcome-Diagnoses of conversion to AD dementia or reversion to normal cognition were made by site clinicians and confirmed by a Central Review Committee. After each follow-up visit, a site psychiatrist or neurologist reviewed the participant's medical history, laboratory tests, and neuropsychological test results (including results from the MMSE and the CDR) to determine an appropriate diagnosis. Diagnoses did not take NPS into account.
Criteria for diagnosing AD were similar to the criteria for diagnosing MCI except that MMSE scores had to be between 20 and 26, CDR had to be 0.5 or 1.0, and the patient had to meet NINCDS-ADRDA criteria for probable AD. Normal cognition was defined by absence of memory complaints, a score on the Logical Memory II subscale of the Wechsler Memory Scale-Revised of 9 or greater (cut-off adjusted for education level), an MMSE score between 24 and 30, and a CDR of 0.
Cognitive outcomes-Cognition was evaluated using the MMSE 21 and two composite indices for memory and executive function. The composite memory index (ADNI-Mem) was based on the memory domains of the MMSE, AD Assessment Scale-Cognition subscale (ADAS-Cog), Rey Auditory Verbal Learning Test (RAVLT), and Logical Memory test. 22 The composite executive function index was based on the Wechsler Memory Scale-Revised Digit Span Test, Digit Span Backwards, Category Fluency, Trails A and B, and the Clock Drawing Test. 23 Functional outcome-The CDR sum of boxes (CDR-SB) has psychometric properties that make it a sensitive measure of both cognitive and functional disability. 24 It was completed by a site clinician who interviewed each subject and his or her study partner. The CDR-SB evaluates five degrees of impairment in each of six categories of cognitive functioning-which include memory, orientation, judgment and problem solving, community affairs, home and hobbies, and personal care-to generate a sum score from 0 to 18. In this analysis, CDR-SB was added to 1 and then log transformed to ascertain a normal distribution.
Neuroimaging and MRI data collection-MRI acquisition and preprocessing have been described previously. 25 Briefly, high-resolution T1 structural images were obtained from all participants on either a 1.5T GE scanner (Waukesha, WI, USA) or a 1.5T Siemens Medical Solutions MRI (Erlangen, Germany) using standardized MRI protocols and acquisition parameters, system-specific corrections for gradient nonlinearity and intensity nonuniformity, and phantom-based monitoring of imaging instruments to control for crosssite variation. Additional preprocessing and quality control procedures included gradient warping, scaling, B1 correction, and N3 inhomogeneity correction on all T1-weighted images as performed by the Mayo Clinic. Cross-sectional image processing was performed using FreeSurfer version 5.1. Each scan is segmented according to an atlas defined by FreeSurfer. This allows for group comparisons at a single time point. 26 Images that did not pass a thorough visual quality control were excluded.
Data analysis
Growth Mixture Modeling (GMM) from Mplus version 7.0 was used to find the smallest number of classes of participants with similar courses of NPS over time. GMM is a method of identifying unique classes within a set of heterogeneous individual growth patterns by examining both the intercept (baseline) and slope (change over time) of individual patterns. It provides insight into the dynamics of developmental processes. More details on GMM can be found elsewhere. 27 A series of models were evaluated beginning with a 1-class solution and ending with a 5-class solution. The optimal number of classes was decided based on Bayesian, Akaike, and Adjusted Bayesian Information Criteria in which lower values indicate a more parsimonious model; and based on the Lo-Mendell-Rubin (LMR) adjusted likelihood ratio test, which compares the current class solution with the class -1 solution to determine whether the two solutions are similar (p > .05) or different (p ≤ 0.05). 27 Each class was described by the shape of trajectory (i.e. intercept and slope) and the number of participants belonging to the class.
After deciding the number of latent classes (n = 3 in the present study), remaining analyses were performed in IBM SPSS 19.0. Analysis of variance (ANOVA) was used to compare continuous baseline demographic and health variables, and Chi-square tests were applied to compare categorical baseline variables.
The association between courses of NPS and conversion/reversion of diagnosis was analyzed using Cox Proportional Hazard Regressions. Generalized Estimating Equation (GEE) modeling with AR(1) working correlated matrix was applied to assess the longitudinal relationships of the latent class of NPS with individual NPS items, as well as other cognitive and functional outcomes adjusted for covariates. Individual NPS items were dichotomous outcomes, while memory, executive function, MMSE, and CDR-SB were continuous outcomes. The equation was: y = β 0 + β 1 Cov 1 + … + β n Cov n + β n+1 Time + β n+2 NPS class + β3 Time × NPS class + ε. Time referred to baseline, and 6-, 12-, 18-, and 24-month follow-ups; ε referred to error term; y referred to each health outcome. The binary logistic function was used for the dichotomous outcome, and the identify link function was used for the continuous outcomes (equal to linear regression). In Cox proportional hazards regression, we used time as the underlying timescale to estimate hazard ratios (HRs) with 95% confidence intervals (CIs) for incident AD cases by NPS class. Two methods (i.e., visual inspection of log minus log survival curves and test of Schoenfeld residuals) were used to verify the proportional hazard assumption. In Cox regression and GEE analyses for cognitive and functional outcomes, age, sex, education, and APOE4 carrier status were included as covariates. All tests were two-tailed and values of p < 0.05 were considered significant in all analyses. Table 1 summarizes the series of model fit statistics of GMM. Synthesizing the model fit indices and the number of participants in each class, the three-class model was considered the best solution. Figure 1 We also examined the individual items of NPS by latent class using GEE (see Table 2 ). The results were consistent with the overall NPS trajectories. The improved class had significantly higher prevalence of individual NPS, except delusion and hallucination, than the stable class at baseline, but their individual NPS (i.e., agitation, depression, apathy, disinhibition, irritability) improved over time. The worsened class had significantly higher prevalence of individual NPS (i.e., delusions, elation, disinhibition, motor disturbance) than the stable class at baseline, and all individual NPS except delusion, hallucination, disinhibition, and appetite worsened significantly faster than the stable class over time. Table 3 displays the demographic and health variables at baseline by latent class using ANOVA or Chi-square test. Baseline differences in age, sex, race, years of education, APOE4 allele carrier status were not significant. Similarly, there were no differences in brain volume or cognitive measures at baseline except in the CDR-SB score. The stable class had the best global functional ability at baseline, while the improved class had the worst.
Results
Latent class of change in NPS over two years
Baseline demographic and health variables by latent class of NPS trajectory
Latent class of neuropsychiatric symptom trajectory and health outcomes over time
Cox proportional hazard regression used the stable class as the referent and controlled for age, sex, education, and APOE4 carrier status. Members of the worsened class were significantly more likely to be diagnosed with incident AD (HR = 1.74, 95% CI = 1.07 -2.84, Wald = 4.89, df = 1, p = 0.027). There was no difference in incidence rate between the improved and stable classes (HR = 1.27, 95% CI = 0.56 -2.91, Wald =0.33, df = 1, p = 0.57) (see Figure 2A) . Reversion from MCI to normal cognition was rare, and rates did not differ significantly between classes (data not shown). Table 4 summarizes the continuous health outcomes by class, taking the stable class as the referent and controlling for age, sex, education, and APOE4 carrier status. Hippocampal and amygdala volumes declined significantly; the worsened class had significantly smaller amygdala volumes at baseline than the stable class; there were no differences in the rate of decline in regional brain volumes by class. All cognitive domains (memory, executive function, and MMSE) declined significantly; the worsened class had significantly better MMSE scores at baseline than the stable class; the declines in all cognitive domains were significantly faster in the worsened class than the stable class; there were no differences in the rate of change in any cognitive domain between the improved and stable classes (see Figures 2B to 2D) . The CDR-SB showed significant decline over time; the improved class had significantly worse CDR-SB scores at baseline than the stable class; CDR-SB scores deteriorated significantly faster in the worsened class than in the stable class (see figure 2E) .
Conclusions
Applying GMM, we found that the longitudinal development of NPS in older adults with a baseline diagnosis of MCI can be classified into three patterns. The majority of participants experienced a consistently low NPS burden, while a small proportion (7.0%) had an NPS burden that worsened over time, and another small proportion (3.2%) had initially high NPS burdens that improved over time. Baseline characteristics such as age, sex, years of education, and APOE4 carrier status did not predict class membership. However, class membership did predict rates of conversion from MCI to AD, as well as cognitive and functional outcomes. In particular, members of the worsened class had higher rates of conversion from MCI to AD, and faster rates of cognitive and functional decline. The rates of change in regional brain volumes did not differ between classes.
The novelty of the present study is that it takes into account the variability of NPS trajectories in individual patients and thereby seeks to refine our understanding of the relationship between NPS and cognitive and functional prognosis. It is premised on the observation that NPS are chronic conditions that develop heterogeneously. [15] [16] [17] Tsoi et al. found that community-dwelling older adults with early signs of executive dysfunction were more likely to develop worsening NPS, 28 while Wetzels et al. found that NPS among nursing home residents tended to improve over a two-year period. 29 Others have found that clinically significant NPS generally remain substantial at follow up. 15, 17 Despite sample differences in these studies, the discrepancy in their findings suggests that NPS trajectories in older adults may be heterogeneous, which is what we found in our sample of patients with MCI.
The diagnostic role of NPS as a sentinel feature of neurocognitive decline is wellestablished. 6, 7, 10, 12 There has been significant effort to characterize baseline NPS profiles that predispose older adults to develop AD. Peters et al. found that the presence of mild NPS increases a patient's risk of progression from MCI to dementia, 4 while Edwards et al. reported that patients with a greater number of NPS at baseline are more likely to convert from MCI to dementia. 13 Three separate studies have found that baseline symptoms of apathy, 30 anxiety, 31 or depression 32 can be associated with conversion from MCI to AD. Work by Steenland et al., however, suggests that it is not merely the presence of depression at baseline but also the pattern of depressive symptoms over time that best predicts a patient's risk of cognitive decline. 18 The present study expands Steenland et al's insight by determining the heterogeneous trajectories of NPS over time and demonstrating that these patterns are associated with different cognitive and functional outcomes.
Examining longitudinal trajectories exposes heterogeneities at the level of individual NPS as well. For example, the overall the level of depression worsened over time; but depression in the improved class got better while depression in the worsened class got worse despite higher levels of depression in the improved class at baseline. These findings appear to validate our model and suggest that individual NPS tend to track with the trajectories we found for overall NPS burden. Further, assessing NPS at a single time point may misinterpret the development of NPS across individuals and its relation to cognitive and functional outcomes.
The literature has not focused on individual characteristics as predictors of NPS. 5, 8, 9 We did not find any baseline characteristics that predicted an individual's trajectory of NPS burden. But different individual characteristics may predict the development of particular NPS. Geda et al. found gender differences in the types of NPS exhibited by cognitively normal older adults who go on to develop MCI. 3 We did not find that the course of NPS predicted brain region volumes. There are two potential explanations. First, our analysis considered brain volume, and NPS may be more related to regional function or connectivity. 6 Second, some clusters of NPS are attributed to specific areas of the brain (e.g. the frontal symptoms of apathy, disinhibition, and irritability). 33, 34 Grouping these different clusters together may have obscured relationships between regional brain volumes and NPS.
Several limitations to the present study bear mentioning. First, we did not control for medication use. Psychotropic drugs and cholinesterase inhibitors are often used to help cognitive function and alleviate NPS in older adults. 35, 36 Second, the NPI-Q may be biased by caregiver burden. 37, 38 The newer Neuropsychiatric Inventory-Clinician rating scale (NPI-C) may provide a more objective evaluation of NPS. 37 Third, although we are supported by consistently finding the most pronounced declines in the "worsened" class across multiple clinical domains, we cannot exclude the possibility that generation of the two classes with extreme cases ("improved" and "worsened" classes) may be affected by the regression to mean in addition to the true NPS changes over time. Future comparison of rates and amounts of change to the estimates reported here may help shed light on this issue. Fourth, we did not examine more functional metrics of brain activity, such as cerebral blood flow and functional connectivity. This data is being collected as part of ADNI-2 and may provide insight into the neurobiological underpinnings of NPS. Finally, the ADNI database represents a highly selective sample of participants with low vascular load, relatively high education, and low baseline NPS burden, which may affect the generalizability of the current findings and inject a bias in the sample selection when it comes to the examination of NPS.
Nevertheless, the present study has important implications for clinicians caring for patients with MCI. Regular follow-up may be indispensable to identify early risk factors for progression to dementia. NPS trajectories may have predictive value that is beyond mere presence of NPS at a single time point and independent of well-known risk factors such as age, sex, education level, and APOE4 carrier status. Administering caregivers a brief questionnaire (e.g., NPI-Q) to monitor a patient's NPS may be a convenient and clinically meaningful way to predict longitudinal cognitive and functional changes.
In conclusion, we suggest that patients with MCI experience different NPS trajectories that are associated with different cognitive and functional outcomes over time. Pharmacological and non-pharmacological interventions that target NPS can improve quality of life for both patients and caregivers, 10 and early intervention in AD can delay institutionalization and neurological decline. 39, 40 Further investigation of the longitudinal relationship between NPS trajectories and cognitive and functional outcomes may enhance efforts to diagnose and prevent the risk of developing AD. Early identification and disruption of NPS trajectories associated with poor outcomes may have implications not only for the quality of life of older adults and their caregivers, but also for their cognitive and functional prognosis. Table 2 Presence of Individual NPS by Latent Class using GEE Analysis (B(SE)). 
